Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD7442 in Healthy Chinese Adults
NCT05437289Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 6 more. Started Oct 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05437289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437289.